Study On Pharmacokinetics And Bioavailability Of Omeprazole

An analytical method for the determination of pharmacokinetics andbioavailability of omeprazole in human plasma has been developedbased on liquid chromatography with tandem mass spectrometry. Twocapsule formulations of omeprazole have been administered to 20healthy volunteers. Test formulation was provided by Jilin ProvinceNortheast Asia Pharmaceutical Co., Ltd. and standard referenceformulation was Olsten from Shantou Special Economic RegionTuobin Pharmaceutical Factory. The pharmacokinetic parameters andbioavailability were assessed by concentration–time curves.After the administration of test and reference formulation in 20 healthyvolunteers, the T_max of omeprazole was 2.2±0.6 (mean ±sd) and 2.4 ±0.8 h, separately; C_max was 509.6 ±221.4 and 524.2 ±195.1 ng/mL; t1/2was 1.7 ±1.2 and 1.7 ±1.0 h; AUC_0-t was 1414.9 ±1070.3 and 1510.5±1056.8 ng?h/mL; AUC_0-∞ was 1424.8±1082.9 and 1529.1 ±1087.4ng·h/mL. The bioavailability of test formulation calculated by AUC_0-twas 96.7 ±23.5%.The two capsule formulations were found to be equivalent withcalculated 90% confidence intervals for omeprazole/Olsten ratios of...